649 related articles for article (PubMed ID: 31237727)
1. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Reich K; Rich P; Maari C; Bissonnette R; Leonardi C; Menter A; Igarashi A; Klekotka P; Patel D; Li J; Tuttle J; Morgan-Cox M; Edson-Heredia E; Friedrich S; Papp K;
Br J Dermatol; 2019 Jul; 181(1):88-95. PubMed ID: 30734266
[TBL] [Abstract][Full Text] [Related]
8. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
9. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
10. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Suleiman AA; Khatri A; Oberoi RK; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
[TBL] [Abstract][Full Text] [Related]
11. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
15. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
16. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
[TBL] [Abstract][Full Text] [Related]
18. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]